Magnetic Ventures

Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhance the expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines.

Weave is a company based in the United States that specializes in an artificial intelligence collaboration platform tailored for the biomedicine sector. It focuses on automating the process of generating regulatory submissions, particularly Investigational New Drug applications. The platform streamlines clinical note abstraction, integrates various data types, and facilitates collaboration among regulatory, research and development, and clinical teams. By organizing, editing, and summarizing source materials, Weave enables the creation of submission-ready INDs in just one day. This approach allows researchers to expedite their decision-making processes and enhances the efficiency of drug development.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Project Eaden focuses on the development and licensing of innovative technologies aimed at producing sustainable food and meat alternatives. The company's food technology platform combines advanced methodologies with culinary needs, offering sustainable products that cater to consumers' cravings for meat. By providing alternatives to traditional beef and beef products, Project Eaden seeks to meet the growing demand for environmentally friendly food options while promoting sustainability in the food industry.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

Spotlight Therapeutics, Inc. specializes in the development of gene editing therapeutics designed to target specific cell populations directly within the body. Established in 2017 and based in Hayward, California, the company leverages a biotechnology platform that utilizes CRISPR nuclease effectors for in vivo gene editing. Its innovative approach aims to create next-generation programmable nucleases that enhance treatment options for a variety of conditions. Spotlight Therapeutics is focused on multiple therapeutic areas, including immuno-oncology, ophthalmology, and hematology, and is developing programs to address previously undruggable intracellular gene targets as well as specific monogenic disease targets related to the eye. This targeted gene editing strategy seeks to overcome the challenges associated with traditional delivery methods, thereby providing healthcare providers with improved tools for patient treatment.

Resilience is a technology-driven biomanufacturing company focused on transforming the production of complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. The company aims to enhance access to these advanced treatments by establishing a sustainable network of end-to-end manufacturing solutions that facilitate rapid, safe, and scalable production. Resilience supports its partners throughout the drug development process, offering customized manufacturing capabilities that cater to the unique requirements of biopharmaceuticals, from pre-clinical stages to commercial supply. By fostering innovation in biopharmaceutical manufacturing, Resilience enables clients to concentrate on breakthrough discoveries that improve patient outcomes while also ensuring the resilience of biopharmaceutical supply chains against potential disruptions.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

AppliedVR, Inc. is a Los Angeles-based company founded in 2013 that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management. The company’s flagship product, EaseVRx, is a VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. By integrating principles of cognitive behavioral therapy and mindfulness, EaseVRx provides a comprehensive approach to managing chronic pain, addressing biological, psychological, and social factors. This platform allows patients to self-administer treatment at home, offering flexibility and promoting better quality of life. AppliedVR has established strategic partnerships with prominent healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles, furthering its mission to empower patients in their pain management journey.

SameSky Health is a provider of multicultural engagement and navigation solutions tailored for health plans, providers, and states. The company specializes in connecting payers, providers, and health systems with diverse Medicare patient populations through a patient engagement platform. This platform offers integrated services that include multi-channel messaging, care navigation, and data insights and consultancy. By addressing the unique needs of culturally diverse populations, SameSky Health aims to enhance patient engagement, reduce unnecessary emergency room visits, and ultimately improve health outcomes and the quality of care provided.

Resilience is a technology-driven biomanufacturing company focused on transforming the production of complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. The company aims to enhance access to these advanced treatments by establishing a sustainable network of end-to-end manufacturing solutions that facilitate rapid, safe, and scalable production. Resilience supports its partners throughout the drug development process, offering customized manufacturing capabilities that cater to the unique requirements of biopharmaceuticals, from pre-clinical stages to commercial supply. By fostering innovation in biopharmaceutical manufacturing, Resilience enables clients to concentrate on breakthrough discoveries that improve patient outcomes while also ensuring the resilience of biopharmaceutical supply chains against potential disruptions.

Resilience is a technology-driven biomanufacturing company focused on transforming the production of complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. The company aims to enhance access to these advanced treatments by establishing a sustainable network of end-to-end manufacturing solutions that facilitate rapid, safe, and scalable production. Resilience supports its partners throughout the drug development process, offering customized manufacturing capabilities that cater to the unique requirements of biopharmaceuticals, from pre-clinical stages to commercial supply. By fostering innovation in biopharmaceutical manufacturing, Resilience enables clients to concentrate on breakthrough discoveries that improve patient outcomes while also ensuring the resilience of biopharmaceutical supply chains against potential disruptions.

Emme, Inc. is a healthcare technology company based in San Francisco, California, focused on enhancing women's health through innovative solutions. The company has developed the Emme Smart Case and a corresponding mobile application, which together help women manage their birth control more effectively. The smart case employs multi-sensor technology to track when birth control pills are taken, alleviating the stress of remembering to take them and alerting users when back-up contraception is necessary. Additionally, the app provides a comprehensive health overview by allowing users to track their menstrual cycles, mood, and side effects. Founded in 2000, Emme aims to modernize the birth control experience for women, aligning it with contemporary technological advancements.

Amagma Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2019. The company focuses on the discovery and development of antibody therapeutics aimed at treating inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma targets overactive extracellular proteases that lead to tissue damage and contribute to widespread inflammatory responses. By addressing these mechanisms, the company aims to provide effective and safe therapeutic options for clinicians dealing with such conditions.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.